Synthesis Funding Limited




Investor Report as at 31 December 2015

| Notes in Issuance | |
|--|------------------|
| Programme Limit | R 15 000 000 000 |
| % Notes issued | 18.41% |
| % Notes available for future issuance | 81.59% |
| Total Notes Outstanding - Market Value | R 2 746 567 512 |
| Total Notes Outstanding - Face Value | R 2 761 000 000 |
| Largest daily issuance within reporting cycle - Face Value | R 507 000 000 |
| Number of Series in Issue | 12 |
| Maximum Maturity allowed | 364 days |
| Longest Remaining Maturity - Days | 76 days |
| Shortest Remaining Maturity - Days | 15 days |
| Average Maturity - Days | 45 days |
| Conditions Precedent that prevent issue of Notes (Yes/No) | No |
| Ratings of Notes | F1+(zaf) |

| Facilities | |
|--|--------------------|
| Liquidity | |
| Minimum Liquidity Commitment | R 2 762 900 000.00 |
| Amount drawn down | Nil |
| Programme Wide Credit Enhancement | N/A |
| Programme Wide Credit Enhancement available | N/A |
| Programme Wide Credit Enhancement required | N/A |
| Programme Wide Credit Enhancement drawn down | N/A |

| Assets - General information | | |
|--|-----------------|--|
| Total Assets - Book Value | R 2 751 934 362 | |
| Number of Assets in Program | | |
| Participating Eligible Investment | 1 | |
| Rated Securities | 6 | |
| Rated ABS | 17 | |
| Maximum Legal Maturity | 26.17 Years | |
| Expected Average Maturity | 1.22 Years | |
| Largest % of any Participating Asset (Principal Balance) | 18.33% | |







| | | % of Participating Assets | |
|-----------------------|--|--|--|
| isted/Non Listed | Listed Non-Listed | 37.64% 62.36% | 62% |
| | Total | 100.00% | ■Non-Listed |
| Asset Type | Participating Eligible Investment Rated ABS Rated Security | 0.02% 32.14% 67.84% | #Participating Eligible Investment #Rated ABS #Rated Security |
| | Total | 100.00% | |
| Asset Rating Fitch | AAA(zaf) or equivalent AA+(zaf) or equivalent AA(zaf) or equivalent AA-(zaf) or equivalent N/A | 32.14% 36.67% 31.17% 0.00% 0.02% | 31% BAAA(zaf) or equivalent BAA+(zaf) or equivalent BAA-(zaf) or equivalent BAA-(zaf) or equivalent BAA-(zaf) or equivalent |
| | Total | 100.00% | BIVA |